Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells

Citation
O. Ohno et al., Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells, INT J ONCOL, 18(5), 2001, pp. 1009-1015
Citations number
27
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF ONCOLOGY
ISSN journal
1019-6439 → ACNP
Volume
18
Issue
5
Year of publication
2001
Pages
1009 - 1015
Database
ISI
SICI code
1019-6439(200105)18:5<1009:SGIBSO>2.0.ZU;2-5
Abstract
In the course of our screening for selective growth inhibitors of human umb ilical vein endothelial cells (HUVECs), we isolated sangivamycin from the c ulture filtrate of Streptomyces. It inhibited the growth of HUVECs at simil ar to 30 times lower concentration than that needed to inhibit the growth o f WI-38 human fibroblasts. Structurally-related nucleosides, such as toyoca mycin, tubercidin, and formycins A and B, did not show the differential inh ibition. Although sangivamycin is known to inhibit protein kinase C, other protein kinase C inhibitors did not inhibit the growth of HUVECs selectivel y. Sangivamycin effectively inhibited S-phase induction in HUVECs, like TNP -470 and LLnL, known selective inhibitors. However, unlike them sangivamyci n did not induce p21 expression. On the other hand, sangivamycin was found to inhibit DNA synthesis selectively in HUVECs. Thus, sangivamycin was show n to be a new selective growth inhibitor of HUVECs acting on DNA synthesis.